Black Diamond Therapeutics Inc stock is traded at $1.72, with a volume of 146,448. It is up +3.31% in the last 24 hours and down -4.72% over the past month. Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Previous Close:
$1.66
Open:
$1.65
24h Volume:
146,448
Relative Volume:
0.21
Market Cap:
$98.53M
Revenue:
$70.00M
Net Income/Loss:
-$43.21M
P/E Ratio:
-
EPS:
-$0.7579
Net Cash Flow:
-$34.03M
1W Performance:
-3.65%
1M Performance:
-4.72%
6M Performance:
-39.18%
1Y Performance:
-56.91%
1-Day Range:
$1.64$1.73
1-Week Range:
$1.64$1.96
52-Week Range:
$1.60$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
617-417-5868Address
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS